BLUW vs. PRME, PLX, IKT, IZTC, JATT, CVM, ZIVO, CRTX, ALVR, and FNCH
Should you be buying Blue Water Acquisition Corp. III stock or one of its competitors? The main competitors of Blue Water Acquisition Corp. III include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), AlloVir (ALVR), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
Blue Water Acquisition Corp. III vs. Its Competitors
Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Blue Water Acquisition Corp. III's return on equity of 0.00% beat Prime Medicine's return on equity.
Prime Medicine has a consensus target price of $8.92, suggesting a potential upside of 43.31%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Blue Water Acquisition Corp. III.
Blue Water Acquisition Corp. III has higher earnings, but lower revenue than Prime Medicine.
In the previous week, Prime Medicine had 2 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 3 mentions for Prime Medicine and 1 mentions for Blue Water Acquisition Corp. III. Prime Medicine's average media sentiment score of 0.63 beat Blue Water Acquisition Corp. III's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Prime Medicine beats Blue Water Acquisition Corp. III on 9 of the 11 factors compared between the two stocks.
Get Blue Water Acquisition Corp. III News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blue Water Acquisition Corp. III Competitors List
Related Companies and Tools
This page (NASDAQ:BLUW) was last updated on 10/9/2025 by MarketBeat.com Staff
